KMT2A and acute myeloid leukemia: Of the 54 CN-AML patients, there were 18 (33.3%) FLT3-ITD mutants, 4 (7.4%) FLT3-TKD mutants, 13 (24.1%) NPM1 mutants, and 3 (5.56%) MLL-PTD mutants (Table 3).